* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download document 8265879
Survey
Document related concepts
Adoptive cell transfer wikipedia , lookup
Adaptive immune system wikipedia , lookup
Immune system wikipedia , lookup
Autoimmune encephalitis wikipedia , lookup
Transmission (medicine) wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Neglected tropical diseases wikipedia , lookup
Globalization and disease wikipedia , lookup
Molecular mimicry wikipedia , lookup
Innate immune system wikipedia , lookup
Germ theory of disease wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Transcript
NOD1/2 Immunomodulatory Agonists Therapeu(c for Autoimmune disease Overview The technology offered by Trinity College relates to novel NOD modulators, par<cularly to NOD1 or NOD1 and NOD2 agonists, processes for their prepara<on, pharmaceu<cal composi<ons comprising these modulators and their uses in the treatment of condi<ons for which agonism of NOD receptors is beneficial including inflammatory autoimmune and/or inflammatory diseases, metabolic, infec<ous and cancer diseases. Advantages Background LPM x10 6 IL-10 (pg/ml) NOD1 and NOD2 are two members of the growing family of Nod-‐like receptors characterized by a nucleo<de-‐oligomeriza<on domain (NOD) and ligand-‐ recognizing leucine-‐rich repeats. NOD1 and NOD2 are involved in the recogni<on of pep<doglycan (PGN), major surface component of Gram-‐posi<ve bacteria. The innate immune receptors recognize specific molecules that are commonly found in microbes and 500 host defense responses 12 to eliminate invading induce **the pathogens. In light *** of the role NODs p** lays in 400 pathogenesis of diseases, it 9is desirable to prepare 300 *** modulate NODs ac<vity and hence compounds that 6 have 200u<lity in the treatment of diseases mediated by NODs such as inflammatory, 3metabolic and 100 autoimmune infec<ous and cancer diseases. 0 Con Ex 15 Ex 29 Clinical Scores 3 Vehicle Ex 15 Ex 29 2 PBS Ex 15 Ex 29 0 120 3 6 Another poten<ally major advantage of the approach is that there is the capacity to generate regulatory T cells specific for an an<gen at the site of disease. The effect will be more localized and therefore less likely to result in global suppression, which causes side effects associated with other an<-‐inflammatory approaches. *** Technology and Patent Status ** 1 0 % Weight Loss 0 The advantage of NOD agonists is that there is no need to administer a broadly immunosuppressive agent, but a product that s<mulates the body to make its own an<-‐inflammatory cytokines. Furthermore, since cells of the innate and adap<ve immune system that mediate inflamma<on also make these an<-‐inflammatory cytokines in vivo, they are more likely to be effec<ve at the site of inflamma<on. This should allow for a more specific effect using a synthe<c drug could be delivered by the oral route and may require less frequent administra<on. Thus improving improved pa<ent compliance and be cheaper than exis<ng therapies. 9 12 15 18 *** 110 100 90 A priority patent applica<on has been filed with the EPO # EP14177268.1. The technology is jointly owned by Trinity College Dublin (TCD) and InvivoGen SAS, where TCD has full unfeYered rights to develop and commercialise the NOD agonists for human therapeu<c use, with collabora<ve support from InvivoGen SAS. The NOD agonists have demonstrated efficacy in murine Mul<ple Sclerosis and Ulcera<ve Coli<s. 80 70 0 3 6 9 12 15 Days post EAE induction 18 Experimental Autoimmune Encephalomyeli<s (EAE) murine model-‐ clinical scores and percentage weight loss following treatment with example compounds 15 and 29 The opportunity Trinity College Dublin are seeking to collaborate with and/or licence the technology for further research and development support to progress through to preclinical and clinical trials. Market Therapeu<cs: Synthesis, Formula<on, Processing and Drug Delivery IP Status PCT/EP2015/066203 Applica<on filed EP14177268.1 Opportunity Research collabora<on Available to License Researcher(s) Prof Kingston Mills & InvivoGen SAS Contact Dr. Emily Vereker, Case Manager, Life Sciences [email protected] +353 1 896 4152 Reference: KM01-‐475-‐01